Real-world use of IBI305, a bevacizumab biosimilar, in a tertiary caner-specialized hospital in China
Funding information: Wu Jieping Medical Foundation, Grant/Award Number: 320-6750-2021-2-1
Abstract
What Is Known and Objective
To investigate and describe the real-world use of IBI305, a biosimilar of bevacizumab, across all approved indications in the first 12 months since its entry in National cancer center of China.
Methods
A retrospective, observational study was carried out to describe the demographic and patient characteristics and treatment patterns of the adult patients who received IBI305 from December 2020 to December 2021.
Results and Discussion
Among 259 cases, 186 patients were non-small cell lung cancer (NSCLC), 86 patients were metastatic colorectal cancer (mCRC), five patients were hepatocellular carcinoma (HCC). More than half of the patients initiated IBI305 were bevacizumab-naive. In patients with NSCLC and mCRC, more than 40% of them received IBI305 as first-line therapy. Among pre-exposed patients, the majority of them were switched from reference product (RP) or other biosimilars to IBI305 within 28 days.
What is New and Conclusion
Early evidence from real world data suggests rapid clinical adoption of IBI305 in all approved tumour types.
CONFLICT OF INTEREST
All of the authors had no personal, financial, commercial, or academic conflicts of interest separately.
Open Research
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.
